LIF level is a predictive marker for clinical pregnancy following IVF-ET of patients with fallopian tube obstruction

CURRENT STATUS: POSTED

Zewu Li
Jining Medical University

Ruimei Li
Jining Medical University

Huiying Dai
Jining Medical University

Xiaoyun Li
Jining Medical University

Xiao Han
Jining Medical University

xuenan Wang
Jining Medical University

Aijun Yang
Center for Reproductive Medicine, Affiliated Hospital of Jining Medical University

eyjlws@yeah.netCorresponding Author

DOI:
10.21203/rs.2.24226/v2

SUBJECT AREAS
Endocrinology & Metabolism

KEYWORDS
Embryo culture medium, LIF, Pregnancy outcome, IVF-ET
Abstract
Background: Leukemia inhibitory factor (LIF) has played a vital role in a series of reproductive events, including follicle growth, embryo growth and differentiation. However, it is unclear whether the level of LIF in embryo culture medium can be used as a marker for clinical pregnancy. In this study, we aimed to investigate whether LIF level in embryo culture medium can act as a predictive marker for pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in infertile patients due to tubal problems.

Methods: A total of 104 infertile patients due to tubal problems underwent IVF-ET treatment. The patients were divided into two groups according to whether they were clinically pregnant. The level of LIF in the embryo culture medium was measured, and the correlation between LIF level and embryo quality and clinical pregnancy outcome was analyzed. The embryo culture medium was collected on the day of blastocyst transplantation.

Results: Compared to non-pregnant group, LIF level in the embryo culture medium on the day of blastocyst transplantation was significantly higher in the pregnant group.

Conclusions: LIF level in the embryo culture medium may be used as a non-invasive auxiliary biomarker for predictive clinical pregnancy in infertile patients with tubal problems that using single blastocyst transfer method.

Introduction
The selection of the most competent embryos for transfer is a crucial step for successful pregnancy using assisted reproductive technologies (ART). For decades, in vitro development of mammalian embryos has been performed extensively under laboratory conditions. Detailed morphological assessment is routinely used to select the embryos with the highest implantation potential [1, 2]. Although this method is relatively successful and has led to significant improvement in the pregnancy rate, ART has its limitations, with > 70% of failure rate during ET [3]. In recent decade, further refinements of morphological features for monitoring embryo development have been introduced and semi-automated in a number of different scenarios [4, 5]. However, live birth rate using ART has not increased much over recent years [6, 7]. It is imperative to develop appropriate approaches and
screen ideal biomarkers to evaluate embryo quality and pregnancy outcome.

The process of embryo implantation is an extremely complex physiological event that depends on the development of the embryo and the receptivity of endometrium. Leukemia inhibitory factor (LIF) is a class of cytokines with a wide range of biological functions. Studies have shown that LIF is involved in a series of reproductive events, including follicle growth, embryo growth and differentiation [8]. LIF level in the follicular fluid is abruptly increased before ovulation and its levels in the follicular fluid are positively correlated with egg cell mass. Our previous study has proved that concentrations of LIF in embryo culture medium were higher in pregnancy group following IVF compared non-pregnancy group in PCOS patients. On the basis of this study [9], we tested LIF levels in the culture medium of single embryo and investigated the correlation between LIF level and pregnancy outcome in infertile patients due to tubal problems, which may evaluate whether LIF level in the embryo culture medium can predict the developmental potential of embryos and clinical pregnancy outcomes in women who undergo infertility treatment.

Materials And Methods

Study patients

A total of 118 patients who underwent IVF-ET between February 2018 and March 2019 in the Center for Reproductive Medicine, Affiliated Hospital of Jining Medical University, were recruited for this study. One hundred and eighteen women participated in the study because 14 patients were lost to follow-up. All of participated women had regular menstrual cycles (28 ± 2 days, blood progesterone concentrations measured between the 18th and 21st days of the menstrual cycle, >10 ng/ml in two consecutive cycles) without clinical or bio-chemical hyperandrogenism or polycystic ovary and with no history of any drug intake for at least 3 months. All of them had either fallopian tube obstruction, or normal reproductive health but an infertile male partner. Sex hormone concentrations and routine biochemical examinations of subjects were normal, and patients had no history of genitourinary diseases, or severe cardiovascular, liver or kidney disease. Additional exclusion criteria were smoking and alcohol consumption. The data for all subjects were obtained from clinical and pathologic records including age and history of menstruation. All subjects provided written informed consent in
accordance with Institutional Review Board guidelines for the protection of human subjects. The study received ethical approval from the Institutional Review Board on 16 March 2018.

**Ovarian stimulation and supernatant collection**

All patients were stimulated by the long protocol. Ovarian follicular development was stimulated with recombinant human FSH (Merck Serono, Switzerland) at doses of 225–450 IU/day. Ovulation was triggered by human chorionic gonadotrophin (HCG 4000–10000 IU) (Livzon Pharmaceutical, China) when at least two follicles were 18 mm and half of the remainder were > 15 mm. Oocytes were recovered transvaginally under ultrasound guidance approximately 34.5 h later. All monitoring of controlled ovarian hyperstimulation (COH) as well as egg retrievals and embryo transfers were performed by one of five physicians. Specific methods refer to previous study [9]. Fertilized eggs were cultured to blastocysts. All embryos were graded microscopically according to Gardner grading standard [10]. All patients chose to transplant the embryo at the blastocyst stage on the fifth day. Each patient selected the embryo with the highest morphological score for single-embryo transfer. All embryo transfers were performed using a Wallace catheter under direct ultrasound guidance 120 h after egg retrieval.

**LIF and β-HCG Assay**

LIF levels were assayed using a specific sandwich enzyme ELISA kit (RD) using a specific monoclonal antibody (mAb). When embryos were transferred to 50 μL droplets, they were transferred together with a small amount of medium. To ensure that equal volume of embryo supernatant was tested, 100 μL of dilution buffer were then added to the microplate testing wells. Forty microliters of embryo supernatant from each droplet were loaded manually into the wells. The standard substance in LIF kit was diluted to give a calibration curve within the range value of the embryos. embryo culture supernatant LIF concentrations were measured by enzyme-linked immunosorbent assay (R and D Systems, USA). Both inter-assay and intra-assay coefficients of variation for LIF assays were less than 10%. The lower limit of detection for LIF was 8 pg/ml. The LIF concentration was determined by the absorbance at 450 nm on the EL800 Universal Microplate Reader (Bio-Tek Instruments Inc., Winooski, VT). Venous blood (2 ml) was collected on the third day of the menstrual cycle after fasting. If
subjects had oligomenorrhea or amenorrhea, fasting venous blood could be collected at any time. The concentrations of serum oestradiol, FSH, LH, pro-gestosterone, testosterone and prolactin (PRL), and follicular fluid oestradiol and progesterone, were measured by chemiluminescence (Roche, Switzerland). The lower limit of detection for oestradiol, FSH, LH, progesterone, testosterone and PRL were 18.4 pmol/l, 0.1 IU/l, 0.1 IU/l, 0.095 nmol/l, 0.087 nmol/l and 0.996 mIU/mL, respectively.

**Luteal support and judgment of pregnancy outcome**

After fertilization, progesterone (Abbott, the Netherlands) was administered by intramuscular injection at a dose of 60 mg per day and continued for 14 days for corpus luteum support. If pregnancy was confirmed, progesterone administration was continued until the 10th week of pregnancy. Biochemical pregnancy was defined as blood HCG >10 IU/L on the 14th day of transplantation. Clinical pregnancy was confirmed with ultrasound examination of the number of gestational sacs and fetal heartbeat on approximately the 64th day after embryo transfer.

**Statistical Analysis**

Differences between groups were evaluated for statistical significance by Student’s t test or Mann-Whitney rank sum test, depending on whether the data were normally distributed. Receiver operating characteristic (ROC) curve analysis was used to analyze the cut off value of LIF concentration and their sensitivity/specificity. Significant P values were set at <0.05. The data were expressed as mean ± standard deviation (SD). The data between two samples were compared by Mann-Whitney U-test. The relationship between the parameters was analysed by Pearson correlation analysis. All calculated P-values were two-sided, and P < 0.05 was used to determine statistical significance. Statistical analyses were performed using GraphPad Prism software (GraphPad Software, USA) and SPSS 18.0 software (SPSS Inc, Chicago, IL, USA).

**Results**

**Clinicopathological characteristics of 104 infertile women with tubal problems**

The cause of infertility in all patients was tubal obstruction. Because 39 pg/mL is the median value, we choose 39 pg/mL as the demarcation point for the two groups. The patients were divided into two
groups according to LIF levels: low LIF group (<39 pg/mL, 52 cases) and high LIF group (≥39 pg/mL, 52 cases). The average age in the high LIF group was 31.73±5.01 years old, and 33.92±4.69 years old in the low LIF group. There were no significant differences in basal FSH level, LH level, E2 level and endometrial thickness between high LIF and low LIF groups. The ovulation induction programs were long protocol. There were 14 cases of primary infertility and 38 cases of secondary infertility in the high LIF group, and 10 cases of primary infertility and 42 cases of secondary infertility in the low LIF group. The pregnancy rate in the high LIF group (57.69%) was obviously higher than that in the low LIF group (44.23%) (Table 1).

**Comparison of LIF level in the culture medium between high quality embryos and inferior embryos**

Total 370 samples of embryo culture medium were collected from all subjects (pregnant and non-pregnant subjects). According to the Gardner blastocyst scoring criteria, the culture medium was divided into high quality embryo group (4BC and above, n=196) and inferior embryo group (less than 4BC, n=174). In the pregnant subjects, LIF level in the high-quality embryo group (67.12±7.91 pg/mL) was higher than that in the inferior embryo (62.74±8.55 pg/mL) (Fig. 1A), but the difference was not statistically significant. Similarly, in non-pregnant group, the LIF level in the high-quality embryo group (48.06 ± 8.49 pg/mL) was higher than that in the inferior embryo group (43.89 ± 9.17pg/mL) (Fig. 1B), but the difference was also not statistically significant.

**Predictive potential of LIF level in embryo culture medium for clinical pregnancy outcomes**

After 10 weeks of transplantation, the pregnancy outcome of patients was examined by B-ultrasound. According to the presence of gestational sac by B-ultrasound, the patients were divided into pregnant and non-pregnant groups. We found that the level of LIF in embryo culture medium from pregnant group was 52.41±7.76 pg/mL, which was significantly higher than that from non-pregnant group with LIF level of 37.45±9.49 pg/mL(P<0.05) (Fig. 2A). Meanwhile, we found that the level of β-HCG in embryo culture medium from pregnant group was 1.44±0.49 IU/L, which was also significantly higher than that from non-pregnant group with its level of 1.18±0.27IU/L (P<0.05) (Fig 2B). To evaluate the potential of LIF level and β-HCG level in embryo culture medium in predicting clinical pregnancy,
receiver operating characteristic (ROC) curves were plotted, and the area under the curve (AUC) values were determined with the highest specificity and sensitivity, which were used to set the optimal prediction point. Optimal prediction point, sensitivity, specificity and AUC value of the potential of LIF level in embryo culture medium in predicting clinical pregnancy were 36.68 pg/mL, 82.6%, 65.5% and 0.762 (95%CI: 0.671–0.853) respectively (Fig. 2C). The AUC of the potential of β-HCG level in embryo culture medium in predicting clinical pregnancy were 0.819 (95%CI: 0.729–0.908). The AUC of the potential of LIF level combined with β-HCG level in embryo culture medium in predicting clinical pregnancy were 0.834 (95%CI: 0.752–0.915) respectively Our research shows that the combination of A and B is more predictive of pregnancy than their individual predictive power.

**Univariate and multivariate logistic regression analyses for clinical pregnancy outcome of patients who underwent IVF-ET**

Using univariate and multivariate analyses, we found no statistically significant correlations between basal FSH level, LH level, endometrial thickness, E2 and pregnancy outcomes (Table 2). We found that age (p=0.041) and LIF level in embryo culture medium (p=0.02) were important predictive factors for clinical pregnancy outcomes (Table 3).

**Discussion**

In IVF-ET, how to select the most development potential embryos is the key for successful pregnancy. At present, the morphology screening of embryos is widely used. However, there are some limitations for morphology screening. For example, high quality of embryo morphology may not represent absolute good development potential embryos. There is a need to find additional or complementary evaluations for embryo quality or developmental potential. Researchers have explored a variety of effective methods to select the best potential embryos to improve clinical pregnancy outcomes for IVF-ET. Using morphological monitoring, numerous morphological features related to embryo quality have been described, such as cell cycle timing, compaction times and cell shape [11, 12]. Analysis of the embryonic secretome (proteins that are produced and secreted by the developing embryo) could provide a non-invasive approach for embryo assessment [13]. Identification of a biomarker in human embryo culture medium that relates to embryo quality and implantation potential could be an
invaluable tool in conjunction with morphological parameters during embryo selection for transfer [14]. Assessment of embryonic proteome has been of particular interest and provides a snapshot of cellular function and embryo physiology. In the present study, we assessed the production of LIF in embryoculture media from individual human blastocyst. The results showed that LIF level in embryo culture medium had a good correlation with clinical pregnancy rate. The embryos for the patients who became pregnant showed higher level of LIF in their culture medium compared with the embryos for the patients who were not pregnant.

The success of ART pregnancy is closely related to follicular development, number of ovum, fertilization, embryo development and implantation. The most critical process of them is embryo implantation into the endometrium. LIF is a secretory glycoprotein, which is a member of interleukin (IL)-6 family. It was named LIF because it can inhibit the growth of myeloid leukemia cell line M1 and promote differentiation [15]. It has been demonstrated that LIF has ability to inhibit the differentiation and maintain the proliferation of embryonic stem cells. LIF is involved in all aspects of reproductive activities, including follicular development, embryo implantation, growth, development, and differentiation. Meanwhile, LIF was found to be associated with the occurrence of the infertility, recurrent abortion and other diseases. LIF transcripts are expressed in many tissues during embryonic development. Perrier et al. found the expression of LIF gene in mouse embryonic germ cells from 3.5 to 12.5 days [16]. Another study found that the best effect of LIF during blastocyst formation is to promote the embryonic development [17]. In the present study, LIF was detected in the embryo culture medium by ELISA with high sensitivity, which further confirmed the preimplantation embryos have the ability to synthesize and secrete LIF, which may promote embryo development via autocrine pathway. However, additional studies are required for further development of a quick, high-throughput system to adequately determine embryonic LIF production from individual embryos prior to clinical application. This may provide the laboratory embryologist or infertility physician an opportunity to determine the quality of embryo, thus improving pregnancy outcome and minimizing multiple gestations.

Studies have shown that medium LIF can promote embryonic development, accelerate embryonic
hatch, improve embryonic developmental potential [18]. Kauna etc found that the addition of LIF to mouse embryo culture medium could promote the development of preimplantation mouse embryos [19]. However, the effect of LIF on embryonic development is different at different time points of LIF addition. The effect of LIF on embryo development was the strongest during blastocyst formation. LIF plays roles in embryogenesis in two ways: inhibit the differentiation of inner cell mass to maintain the pluripotency of embryos; and stimulate the proliferation of trophoblast ectoderm. A key step in mammalian pregnancy is blastocyst implantation. Embryo implantation is a complex physiological process. Successful implantation is the result of the coordination between endometriosis and invasive blastocyst. Recent studies [20] have shown that LIF is a prerequisite for blastocyst implantation. Moreover, LIF can play an important role in influencing endometrial receptivity and maternal-fetal interface during early pregnancy. β-HCG concentration may be applied as an indicator of potential developmental progress of the embryo [21]. In our study, we also found that pregnancy predictions in combination with LIF and β-HCG are significantly better than their individual predictive power.

Conclusions
In summary, quantitative detection of LIF in embryo culture medium is expected to be a parameter for selecting high-quality embryos for transfer in addition to morphology in IVF clinics. Moreover, blastocyst-derived LIF may be used an indicator for embryo quality and the prediction of pregnancy outcome. However, the findings in this study should be validated in a large cohorts of subjects who undergo IVF-ET, from multiple IVF clinics in different cities.

Abbreviations
assisted reproductive technologies (ART); Leukemia inhibitory factor (LIF); prolactin (PRL); Receiver operating characteristic (ROC); mean ± standard deviation (SD); area under the curve (AUC);
interleukin (IL)

Declarations

Ethics approval and consent to participate
The study received ethical approval from the Institutional Review Board on 16 March 2018. All subjects provided written informed consent in accordance with Institutional Review Board guidelines for the protection of human subjects.
Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflict of interest.

Funding

This work was supported by grants from the National Natural Science Foundation (81701526).

Authors’ contributions

Zewu Li and Aijun Yang proposed the concept and designed the study. Ruimei Li, Huiying Dai and Xiaoyun Li participated in the design of the study and performed the statistical analysis. Xiao Han and Xuenan Wang participated in its design and coordination and helped to draft the manuscript. Zewu Li analyzed and interpreted the data and prepared the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Ebner T, Moser M, Sommergruber M, Tews G. Selection based on morphological assessment of oocytes and embryos at different stages of preimplantation development: a review. Hum Reprod Update. 2003;9(3):251-62.

2. Liu Y, Chapple V, Feenan K, Roberts P, Matson P. Time-lapse deselection model for human day 3 in vitro fertilization embryos: the combination of qualitative and quantitative measures of embryo growth. Fertil Steril. 2016;105(3):656-62.

3. Holm P, Booth PJ, Callesen H. Kinetics of early in vitro development of bovine in vivo- and in vitro-derived zygotes produced and/or cultured in chemically defined or
serum-containing media. Reproduction. 2002;123(4):553-65.

4. Pribenszky C, Losonczi E, Molnar M, Lang Z, Mátys S, Rajczy K, Molnár K, Kovács P, Nagy P, Conceicao J, Vajta G. Prediction of in-vitro developmental competence of early cleavage-stage mouse embryos with compact time-lapse equipment. Reprod Biomed Online. 2010;20(3):371-9.

5. Rubio I, Galan A, Larreategui Z, Ayerdi F, Bellver J, Herrero J, Meseguer M. Clinical validation of embryo culture and selection by morphokinetic analysis: a randomized, controlled trial of the EmbryoScope. Fertil Steril. 2014;102(5):1287-94.

6. Ferraretti AP, Goossens V, Kupka M, Bhattacharya S, de Mouzon J, Castilla JA, Erb K, Korsak V, Nyboe Andersen A; European IVF-Monitoring (EIM) Consortium for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE. Hum Reprod. 2013;28(9):2318-31.

7. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D'Hooghe T, Castilla JA, Calhaz-Jorge C, De Geyter C, Goossens V; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHREdagger. Hum Reprod. 2014;29(10):2099-113.

8. Aghajanova L. Leukemia inhibitory factor and human embryo implantation. Ann N Y Acad Sci. 2004;1034:176-83.

9. Li Z, Zhu Y, Li H, Jiang W, Liu H, Yan J, Chen ZJ, Li W. Leukaemia inhibitory factor in serum and follicular fluid of women with polycystic ovary syndrome and its correlation with IVF outcome. Reprod Biomed Online. 2018;36(4):483-9.

10. Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, Hesla J. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. Hum
11. Papanikolaou EG, Kolibianakis EM, Tournaye H, Venetis CA, Fatemi H, Tarlatzis B, Devroey P. Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. Hum Reprod. 2008;23(1):91-9.

12. Somfai T, Inaba Y, Aikawa Y, Ohtake M, Kobayashi S, Konishi K, Imai K. Relationship between the length of cell cycles, cleavage pattern and developmental competence in bovine embryos generated by in vitro fertilization or parthenogenesis. J Reprod Dev. 2010;56(2):200-7.

13. Seli E, Vergouw CG, Morita H, Botros L, Roos P, Lambalk CB, Yamashita N, Kato O, Sakkas D. Noninvasive metabolomic profiling as an adjunct to morphology for noninvasive embryo assessment in women undergoing single embryo transfer. Fertil Steril. 2010;94(2):535-42.

14. Katz-Jaffe MG, McReynolds S, Gardner DK, Schoolcraft WB. The role of proteomics in defining the human embryonic secretome. Mol Hum Reprod. 2009;15(5):271-7.

15. Aghajanova L. Update on the role of leukemia inhibitory factor in assisted reproduction. Curr Opin Obstet Gynecol. 2010.;22(3):213-9.

16. Perrier DS, Charlet-Renard C, Berndt S, Dubois M, Munaut C, Goffin F, Hagelstein MT, Noël A, Hazout A, Foidart JM, Geenen V. Human chorionic gonadotropin and growth factors at the embryonic-endometrial interface control leukemia inhibitory factor (LIF) and interleukin 6 (IL-6) secretion by human endometrial epithelium. Hum Reprod. 2004;19(11):2633-43.

17. Tsai HD, Chang CC, Hsieh YY, Hsu LW, Chang SC, Lo HY. Effect of different concentrations of recombinant leukemia inhibitory factor on different development stage of mouse embryo in vitro. J Assist Reprod Genet. 2000;17(6):352-5.
18. Grazul-Bilska AT, Pant D, Luther JS, Borowicz PP, Navanukraw C, Caton JS, Ward MA, Redmer DA, Reynolds LP. Pregnancy rates and gravid uterine parameters in single, twin and triplet pregnancies in naturally bred ewes and ewes after transfer of in vitro produced embryos. Anim Reprod Sci. 2006.;92(3-4):268-83.

19. Kauma SW, Matt DW. Coculture cells that express leukemia inhibitory factor (LIF) enhance mouse blastocyst development in vitro. J Assist Reprod Genet. 1995;12(2):153-6.

20. Choi Y, Kim HR, Lim EJ, Park M, Yoon JA, Kim YS, Kim EK, Shin JE, Kim JH, Kwon H, Song H, Choi DH. Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeate Implation Failure (RIF). Plos One. 2016;11(6):e157696.

21. Keane KN, Mustafa KB, Hinchliffe P, Conceicao J, Yovich JL. Higher beta-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers. Reprod Biomed Online. 2016;33(2):149-60.

Tables
Table 1. Characteristics of the 104 infertile women with tubal factors
| Factors                          | High         | Low          |
|---------------------------------|--------------|--------------|
| Number of patients              | 52           | 52           |
| Average age (years) (mean±SD)   | 31.73±5.00   | 33.92±4.69   |
| Basal FSH levels (UI/l) (mean±SD)| 7.952±3.453  | 7.652±1.828  |
| Basal LH levels (UI/l) (mean±SD)| 5.443±2.448  | 5.133±1.96   |
| E2 (UI)(mean±SD)                | 896.5±284    | 815.3±289.4  |
| Endometrium (mm) (mean±SD)     | 1.096±0.1849 | 1.090±0.2088 |
| Primary                         | 14           | 10           |
| Secondary                       | 38           | 42           |
| Pregnancy                       | 30           | 23           |
| Pregnancy rate(%)               | 57.69%       | 44.23%       |
| LIF                             | 65.39±8.33   | 46.59±9.27   |

Table 2 Univariate analysis of various factors in patients with pregnancy outcome

| Factors                              | B     | SE     | Wald  | HR  | 95% CI Low | 95% CI Upper | P value |
|--------------------------------------|-------|--------|-------|-----|------------|--------------|---------|
|                                     |       |        |       |     |            |              |         |
| Age                                  | 0.148 | 0.068  | 4.768 | 0.863| 0.756      | 0.985        | 0.041   |
| Basal FSH                            | 0.020 | 0.105  | 0.036 | 0.98 | 0.799      | 1.203        |         |
| Basal LH                             | 0.099 | 0.134  | 0.551 | 0.905| 0.697      | 1.177        |         |
| Endometrial thickness                | 1.822 | 1.493  | 1.489 | 6.182| 0.332      | 11.525       |         |
| E2                                   | 0.232 | 0.001  | 0.058 | 1.00 | 0.998      | 1.002        |         |
| LIF                                  | 0.034 | 0.013  | 6.42  | 1.034| 1.008      | 1.061        |         |

Table 3 Multivariant analysis of various factors in patients with pregnancy outcome

| Factors | B     | SE     | Wald  | HR  | 95% CI Low | 95% CI Upper | P value |
|---------|-------|--------|-------|-----|------------|--------------|---------|
|         |       |        |       |     |            |              |         |
| Age     | 0.135 | 0.071  | 3.554 | 0.874| 0.760      | 1.005        | 0.041   |
| LIF     | 0.033 | 0.014  | 5.401 | 1.034| 1.005      | 1.063        | 0.02    |

Figures
Figure 1

LIF level in high quality embryo culture medium and inferior quality embryo culture medium.

A LIF level in high quality and inferior quality embryo culture medium of pregnancy group; B LIF level in high quality and inferior quality embryo culture medium of non-pregnancy group.
Figure 2

A. LIF level in embryo culture supernatant between Pregnancy and Non-pregnancy group. B. β-HCG level in embryo culture supernatant between Pregnancy and Non-pregnancy group. C. ROC analysis of LIF and β-HCG to assess the predictive powers of clinical pregnancy.